Special Issue

Marine Toxins from Venom: Potential Pharmaceutical and Medicinal Application Exploration

Message from the Guest Editor

Bioactive molecules continue to be of increasing interest as potential therapeutics and therapeutic leads. Venoms are an extensive natural source of highly potent and specific bioactive compounds, in particular peptides and proteins. Venomous marine organisms are no exception and, although they have provided the source for the clinically available peptide drug for the treatment of chronic pain, Prialt®, the diverse resource they offer remains largely uncharted. The Special Issue of *Marine Drugs* titled "Marine Toxins from Venom: Potential Pharmaceutical and Medicinal Application Exploration" aims to explore the current state and future perspectives of bioactive molecule discovery from the venom of marine organisms and their potential in pharmaceutical, pharmacological tool, and medicinal applications. Original manuscripts and reviews of the current literature related to the discovery, characterization, biological target modulation, and clinical development of bioactive molecules possessing therapeutic potential isolated from the venom of marine organism are encouraged.

Guest Editor

Dr. David Wilson

Centre for Biodiscovery and Molecular Development of Therapeutics (CBMDT), Australian Institute of Tropical Health and Medicine (AITHM), James Cook University, McGregor Road, Smithfield, Cairns 4878, Australia

Deadline for manuscript submissions

closed (29 February 2020)



Marine Drugs

an Open Access Journal by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



mdpi.com/si/22230

Marine Drugs
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
marinedrugs@mdpi.com

mdpi.com/journal/marinedrugs





an Open Access Journal by MDPI

Impact Factor 5.4 CiteScore 10.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

